Anti-IGF-1R Monoclonal Antibody

Innovent Biologics' SYCUME® (teprotumumab N01) has received NMPA approval as China's first IGF-1R monoclonal antibody for treating thyroid eye disease, ending a 70-year treatment innovation drought.

TEPEZZA, the first FDA-approved treatment for thyroid eye disease, generated $1.9 billion in sales for 2024, with $460 million in Q4 alone, addressing a critical unmet need for patients with limited treatment alternatives.

Linsitinib, an oral small molecule, significantly reduced proptosis in patients with active, moderate to severe thyroid eye disease (TED) in a Phase 2b/3 trial.

Sling Therapeutics appointed Andrew Guggenhime to its Board of Directors, leveraging his extensive biopharma experience to advance clinical programs.

Percheron Therapeutics halted its Phase 2b trial of avicursen in non-ambulatory Duchenne muscular dystrophy patients due to the drug failing to meet its primary endpoint.